Our Parallel Trade Expertise

News May 11, 2022

Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups

We acquired RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction(...)

MedTech Patient Engagement Pharma

Multimedia May 10, 2022

VacciTalks: Behind the Scenes: Challenging Race of Vaccine Development

Join the 2nd episode of VacciTalks where together with vaccine expert Roberto Camerini we will peek behind the scenes of vaccine development and get an insider look at the difficulties,(...)

Market Access

Events May 9, 2022

7e Journée start-up innovantes du dispositif médical

Clinical Digital Health Market Access MedTech Research & Development

Multimedia April 28, 2022

Alira Health’s Transformation Talks: Real-World Data to Support HTAs in Europe

Learn more about RWD as a support in HTAs and its direct impact on HTAs budgets, results, and even patient outcomes by listening to this episode of Transformation Talks.

Clinical Market Access RWE

Publications April 20, 2022

White Paper: Next Generation Therapies: Access, Pricing and Ethical Issues in Perspective

In this white paper, we will explore wide range of new therapies we term “Next Generation Therapies” and challenges related to them.

Market Access

News April 5, 2022

Alira Health Strengthens Clinical Operations with the Acquisition of Sourcia

We acquired a full-service Contract Research Organization (CRO), Sourcia, that provides services for Phase I to Phase IV clinical trials with a focus on biotech, medical devices, and(...)

Clinical MedTech Patient Engagement Pharma Regulatory Research & Development

Publications March 31, 2022

The FDA’s Project Orbis Can Speed up the Delivery of Your New Oncology Drug to Global Markets

Are you developing an oncology drug? Project Orbis, a program coordinated by the U.S. Food and Drug Administration (FDA), allows you to register your product in several countries with(...)

Pharma Regulatory